RE:irrational exuberance
The more I learn about CXR the better it gets in my mind. Mark was reminding us on Friday (BNN) that Amco is not a normal acquisition for CXR. The strategy of CXR is actually to just buy drugs, not companies. what he was trying to get investors to understand is that CXR is now perfectly organized to keep with that original strategy of just buying drugs. The Amco deal gives them a worldwide footprint to have distribution for the drugs they will buy. this gives market scale and diversification to those drugs they buy, which dilutes risk for the shareholder. Their tax structure gives them an advantage, and their small share float allows for ace up the sleeve equity financings. these subtle things are a big separation from VRX.